Showing results (131-140 of 172) with videos related to
Sort By:
Pageof 18
Leukemia & Lymphoma|June 7, 2026
Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic centerHua-Jay J Cherng, David DeStephano, Patrick Gould, et al.Blood Advances|September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphomaPamela B Allen, Xinyan Lu, Qing Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomasIssa F Khouri, Rima M Saliba, Chitra Hosing, et al.Clinical Lymphoma, Myeloma & Leukemia|January 2, 2013
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trialJason R Westin, Michael A Thompson, Vince D Cataldo, et al.Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.British Journal of Haematology|August 12, 2015
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphomaDai Chihara, Barbara Pro, Sanam Loghavi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteinsCatherine M Bollard, Stephen Gottschalk, Vicky Torrano, et al.Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.Pageof 18